Skip to main content

Premarket Movers Wednesday - Chewy, Walgreens, Pfizer, Apple

Stocks moving in premarket trading on Wednesday include Chewy, Pfizer, Apple, BioNTech, BlackBerry and Walgreens.

Stock futures wobbled Wednesday as investors awaited details of President Joe Biden's infrastructure plan.

Dow Futures Lower Ahead of Biden Infrastructure Plan; Bond Yields Rise

Here are some of the top movers during premarket trading on Wednesday.

1. Chewy CHWY | Up 13%

Shares of Chewy  (CHWY) were higher after the online pet-supplies provider reported its first quarterly profit after the bell Tuesday. Revenue nearly doubled to $2 billion amid a surge in online orders during the pandemic.

"Overall, we see 2020 and the impact of COVID as much more than just a one-time growth accelerator," Chief Executive Sumit Singh and Chief Financial Officer Mario Marte wrote in a letter to investors.

2. BioNTech BNTX | Up 3.2%

American depositary receipts of BioNTech  (BNTX)  advanced after Pfizer  (PFE)  said its coronavirus vaccine developed in partnership with the German drugmaker was 100% effective in a late-stage study of adolescents aged 12 to 15. 

3. Apple AAPL | Up 1.6%

Shares of Apple  (AAPL)  moved higher after analysts at UBS boosted their price target on the tech giant, citing stable iPhone demand and its potential move into the electric-vehicle market.

UBS analyst David Vogt lifted his rating on Apple to buy from neutral while boosting his price target to $142 from $115.

4. Walgreens Boots Alliance WBA | Up 2.5%

Shares of Walgreens  (WBA)  rose Wednesday after the drugstore operator reported better-than-expected quarterly earnings and raised its full-year guidance for the fiscal year.

5. BlackBerry BB | Down 5.3%

Shares of BlackBerry  (BB)  slipped after the communications software company missed fourth-quarter revenue expectations set by Wall Street analysts.

6. Pfizer PFE | Up 0.4%

Shares of Pfizer  (PFE)  rose after the company said its coronavirus vaccine developed in partnership with the German drugmaker BioNTech  (BNTX)  was 100% effective in a late-stage study of adolescents aged 12 to 15.